DefenCath: Closing the Last Open Door on Dialysis Infections

DefenCath: Closing the Last Open Door on Dialysis Infections

From a decade of FDA setbacks to a 71% breakthrough — how CorMedix turned a hemodialysis lifeline into a defended one.

More than 800,000 Americans live with kidney failure, and roughly half of them rely on hemodialysis to stay alive. For tens of thousands of those patients, the front door to their bloodstream is a central venous catheter — a tunneled tube that delivers their three-times-a-week treatment. It is also one of the most dangerous indwelling devices in modern medicine: catheter-related bloodstream infections (CLABSIs) strike an estimated 37,000 outpatient hemodialysis patients in the U.S. each year, and 12–25% of those infections are fatal. For 50 years, the inside of that catheter has been a black box — protected only by saline or heparin between sessions.

CorMedix Therapeutics (NASDAQ: CRMD), based in Parsippany, New Jersey, spent more than a decade and weathered two FDA Complete Response Letters fighting to change that. In November 2023, DefenCath — a taurolidine and heparin antimicrobial catheter lock solution — became the first and only FDA-approved drug of its kind in America. The Phase 3 LOCK-IT-100 trial randomized more than 800 hemodialysis patients and demonstrated a 71% reduction in CRBSI risk versus heparin alone; an independent Data Safety and Monitoring Board halted the study early for demonstrated efficacy.

In this Health Uncensored segment, CorMedix EVP/COO Liz Hurlburt joins Dr. Drew alongside Dallas-based nephrologist Dr. Geoffrey Walker (Chief Medical Officer, Innovative Renal Care) and patient advocate Pesh Patel (founder, A Kidney Life) to explain why American healthcare has rewarded treating CLABSIs more than preventing them, what an antimicrobial — not an antibiotic — really means in an era of rising antimicrobial resistance, and what changes for the patient sitting in the dialysis chair tomorrow morning. A field package shot in Dallas at Dallas Nephrology Associates puts viewers on the dialysis floor and gives Pesh’s story a face. For kidney patients, caregivers, nephrologists, dialysis administrators, and Fox Business viewers tracking the next breakout in healthcare innovation — this is the segment to watch.

Facebook
Twitter
LinkedIn
Pinterest